Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Revenue of Lantern Pharma Inc. (LTRN)
Revenue in 2023 (TTM): $
According to Lantern Pharma Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Lantern Pharma Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-174,843 | $-15,786,689 | $-15,961,534 | $-15,961,534 |
| 2022 | $ | $-154,681 | $-14,422,672 | $-14,259,946 | $-14,087,139 |
| 2021 | $ | $-97,421 | $-12,265,608 | $-12,363,029 | $-12,295,100 |
| 2020 | $ | $-3,388 | $-5,904,802 | $-5,908,190 | $-5,908,190 |
| 2019 | $ | $-1,627 | $-2,426,558 | $-2,428,185 | $-2,428,185 |
| 2018 | $ | $2.54 K | $-1,728,961 | $-1,726,417 | $-1,726,417 |